Aristotle Capital Management’s Edwards Lifesciences EW Stock Holding History

Aristotle Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$784M	Buy	+8,665,712	New	+$726M	1.64%	25

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Aristotle Capital Management's EW Position: Q2 2026 in Review

Aristotle Capital Management opened a new position in Edwards Lifesciences (EW) in Q2 2026: 8,665,712 shares worth $784M. The stake represents 1.64% of the portfolio and ranks #25 among its holdings.

1,164 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Aristotle Capital Management held 8,665,712 shares of Edwards Lifesciences worth $784M as of Q2 2026.
Edwards Lifesciences was a new Aristotle Capital Management position in Q2 2026.
Edwards Lifesciences made up 1.64% of Aristotle Capital Management's portfolio in Q2 2026, its #25 holding.
1,164 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Aristotle Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.